106 related articles for article (PubMed ID: 17603225)
1. Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of once- versus twice-daily dosing.
Matsuki M; Matsuda M; Kohara K; Shimoda M; Kanda Y; Tawaramoto K; Shigetoh M; Kawasaki F; Kotani K; Kaku K
Endocr J; 2007 Aug; 54(4):571-6. PubMed ID: 17603225
[TBL] [Abstract][Full Text] [Related]
2. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus.
Sonnenberg GE; Garg DC; Weidler DJ; Dixon RM; Jaber LA; Bowen AJ; DeChemey GS; Mullican WS; Stonesifer LD
Ann Pharmacother; 1997 Jun; 31(6):671-6. PubMed ID: 9184703
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
[TBL] [Abstract][Full Text] [Related]
4. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.
Rosenstock J; Samols E; Muchmore DB; Schneider J
Diabetes Care; 1996 Nov; 19(11):1194-9. PubMed ID: 8908379
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, phase III evaluation of the efficacy and safety of a new fixed-dose pioglitazone/glimepiride combination tablet in Japanese patients with type 2 diabetes.
Hiroi S; Sugiura K; Matsuno K; Hirayama M; Kuriyama K; Kaku K; Kawakami K
Diabetes Technol Ther; 2013 Feb; 15(2):158-65. PubMed ID: 23289434
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized, 2-sequence, 2-period, 2-treatment crossover study.
Shin KH; Kim SE; Yoon SH; Cho JY; Jang IJ; Shin SG; Yu KS
Clin Ther; 2011 Nov; 33(11):1809-18. PubMed ID: 22036245
[TBL] [Abstract][Full Text] [Related]
7. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
[TBL] [Abstract][Full Text] [Related]
8. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus.
Campbell RK
Ann Pharmacother; 1998 Oct; 32(10):1044-52. PubMed ID: 9793597
[TBL] [Abstract][Full Text] [Related]
9. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide.
Massi-Benedetti M; Herz M; Pfeiffer C
Horm Metab Res; 1996 Sep; 28(9):451-5. PubMed ID: 8911982
[TBL] [Abstract][Full Text] [Related]
10. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
[TBL] [Abstract][Full Text] [Related]
11. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
Janka HU; Plewe G; Riddle MC; Kliebe-Frisch C; Schweitzer MA; Yki-Järvinen H
Diabetes Care; 2005 Feb; 28(2):254-9. PubMed ID: 15677775
[TBL] [Abstract][Full Text] [Related]
12. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.
Burant CF; Viswanathan P; Marcinak J; Cao C; Vakilynejad M; Xie B; Leifke E
Lancet; 2012 Apr; 379(9824):1403-11. PubMed ID: 22374408
[TBL] [Abstract][Full Text] [Related]
13. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.
Smulders RA; Zhang W; Veltkamp SA; van Dijk J; Krauwinkel WJ; Keirns J; Kadokura T
Diabetes Obes Metab; 2012 Oct; 14(10):937-43. PubMed ID: 22587345
[TBL] [Abstract][Full Text] [Related]
14. Glimepiride pharmacokinetics in obese versus non-obese diabetic patients.
Shukla UA; Chi EM; Lehr KH
Ann Pharmacother; 2004 Jan; 38(1):30-5. PubMed ID: 14742789
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment.
Rosenkranz B; Profozic V; Metelko Z; Mrzljak V; Lange C; Malerczyk V
Diabetologia; 1996 Dec; 39(12):1617-24. PubMed ID: 8960852
[TBL] [Abstract][Full Text] [Related]
16. Glimepiride in type 2 diabetes mellitus Thai patients.
Deerochanawong C; Chandraprasert S; Suthijumroon A; Vichayanrat A; Himathongkam T; Nitiyanant W; Benjasuratawong Y; Suwanwalaikorn S; Sarinnapakorn V; Vongterapak S
J Med Assoc Thai; 2001 Sep; 84(9):1221-8. PubMed ID: 11800292
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic modeling of glimepiride plasma concentration in healthy subjects.
Antonesi IM; Potur R; Potur DM; Ghiciuc CM; Lupuşoru CE
Rev Med Chir Soc Med Nat Iasi; 2011; 115(3):949-53. PubMed ID: 22046814
[TBL] [Abstract][Full Text] [Related]
18. Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride.
Ebato C; Shimizu T; Arakawa M; Mita T; Fujitani Y; Watada H; Kawamori R; Hirose T
Diabetes Res Clin Pract; 2009 Oct; 86(1):31-6. PubMed ID: 19692134
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients.
Rosenkranz B
Horm Metab Res; 1996 Sep; 28(9):434-9. PubMed ID: 8911979
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus.
González-Ortiz M; Guerrero-Romero JF; Violante-Ortiz R; Wacher-Rodarte N; Martínez-Abundis E; Aguilar-Salinas C; Islas-Andrade S; Arechavaleta-Granell R; González-Canudas J; Rodríguez-Morán M; Zavala-Suárez E; Ramos-Zavala MG; Metha R; Revilla-Monsalve C; Beltrán-Jaramillo TJ
J Diabetes Complications; 2009; 23(6):376-9. PubMed ID: 18849173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
